Hospira is voluntarily recalling three lots of the injectable opioid medication Hydromorphone HCl because the glass vials may be broken or cracked, the Food and Drug Administration announced yesterday. Hospira has notified hospitals and others with an existing inventory of the lots subject to this recall that they should stop use and distribution of the remaining units and quarantine them immediately. See the FDA announcement for more information, including the lot numbers. Health care professionals are encouraged to report any related problems or events to the FDA's MedWatch Program. Last week, the AHA and others asked the Drug Enforcement Administration to temporarily adjust the aggregate production quotas for certain injectable opioid medications in short supply to allow other manufacturers to supply product until the shortages resolve.
 

Headline
The Administration for Strategic Preparedness and Response June 16 announced the launch of the Digital Stockpile and Manufacturing Response Network Challenge,…
Headline
Stormee Williams, M.D., senior vice president and chief health equity officer at Children’s Health, shares how her team is identifying food insecurity, why…
Headline
President Trump signed an executive order May 29 that directs the Centers for Disease Control and Prevention and the Advisory Committee on Immunization…
Headline
The Centers for Disease Control and Prevention today released a report highlighting data on patients hospitalized during a 2025 measles outbreak centered in…
Headline
The Centers for Disease Control and Prevention released a Health Alert Network Health Update May 18 informing clinicians about testing available for patients…
Blog
High-quality maternal care is essential to protecting the health of both mom and baby during birth.Sutter Health is taking a proactive, systemwide approach to…